NPI 1811348824: Open Payments
NPI 1811348824. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$300 in 6 payments from 5 companies in 2025. Trend: 2023 $681 · 2024 $793 · 2025 $300
Food & beverage: $300
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 2 | $142 |
| Genentech USA, Inc. | 1 | $89 |
| Biogen, Inc. | 1 | $27 |
| ABBVIE INC. | 1 | $23 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
Products named: Leqembi, Ocrevus, UBRELVY, AIRSUPRA.
